#11 A case of sensory ataxic Guillain-Barre syndrome with immunoglobulin G anti-GM1 antibodies after first dose of COVID-19 BNT162b2 mRNA vaccine (Pfizer): pubmed.ncbi.nlm.nih.gov/34871447/
Reporting of acute inflammatory neuropathies with COVID-19 vaccines: subgroup disproportionality analysis in VigiBase: pubmed.ncbi.nlm.nih.gov/34579259/
Guillain-Barré syndrome after SARS-CoV-2 vaccination in a patient with previous vaccine-associated Guillain-Barré syndrome: pubmed.ncbi.nlm.nih.gov/34810163/
Guillian-Barre syndrome with axonal variant temporally associated with Modern SARS-CoV-2 mRNA-based vaccine: pubmed.ncbi.nlm.nih.gov/34722067/
Guillain-Barre syndrome after the first dose of SARS-CoV-2 vaccine: a temporary occurrence, not a causal association: pubmed.ncbi.nlm.nih.gov/33968610/
SARS-CoV-2 vaccines can be complicated not only by Guillain-Barré syndrome but also by distal small fiber neuropathy: pubmed.ncbi.nlm.nih.gov/34525410/
Clinical variant of Guillain-Barré syndrome with prominent facial diplegia after AstraZeneca 2019 coronavirus disease vaccine: pubmed.ncbi.nlm.nih.gov/34808658/
Bell’s palsy after inactivated vaccination with COVID-19 in a patient with a history of recurrent Bell’s palsy: case report: pubmed.ncbi.nlm.nih.gov/34621891/
Beware of neuromyelitis optica spectrum disorder after vaccination with inactivated virus for COVID-19: pubmed.ncbi.nlm.nih.gov/34189662/
Neuromyelitis optica in a healthy woman after vaccination against severe acute respiratory syndrome coronavirus 2 mRNA-1273: pubmed.ncbi.nlm.nih.gov/34660149/
Acute bilateral bilateral optic neuritis/chiasm with longitudinal extensive transverse myelitis in long-standing stable multiple sclerosis after vector-based vaccination against SARS-CoV-2: pubmed.ncbi.nlm.nih.gov/34131771/
A case series of acute pericarditis after vaccination with COVID-19 in the context of recent reports from Europe and the United States: pubmed.ncbi.nlm.nih.gov/34635376/
Miller-Fisher syndrome and Guillain-Barré syndrome overlap syndrome in a patient after Oxford-AstraZeneca SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34848426/.
Immune-mediated disease outbreaks or new-onset disease in 27 subjects after mRNA/DNA vaccination against SARS-CoV-2: pubmed.ncbi.nlm.nih.gov/33946748/
Case report: anti-neutrophil cytoplasmic antibody-associated vasculitis with acute renal failure and pulmonary hemorrhage can occur after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34859017/
Lobar hemorrhage with ventricular rupture shortly after the first dose of a SARS-CoV-2 mRNA-based SARS-CoV-2 vaccine: pubmed.ncbi.nlm.nih.gov/34729467/.
Gross hematuria after severe acute respiratory syndrome coronavirus 2 vaccination in 2 patients with IgA nephropathy: pubmed.ncbi.nlm.nih.gov/33771584/
Bell’s palsy after vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and a nested case-control study: pubmed.ncbi.nlm.nih.gov/34411532/
Allergic reactions, including anaphylaxis, after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine – United States, December 14 to 23, 2020: pubmed.ncbi.nlm.nih.gov/33641264/
Allergic reactions, including anaphylaxis, after receiving the first dose of Modern COVID-19 vaccine – United States, December 21, 2020 to January 10, 2021: pubmed.ncbi.nlm.nih.gov/33641268/
Prolonged anaphylaxis to Pfizer 2019 coronavirus disease vaccine: a case report and mechanism of action: pubmed.ncbi.nlm.nih.gov/33834172/
Anaphylaxis reactions to Pfizer BNT162b2 vaccine: report of 3 cases of anaphylaxis following vaccination with Pfizer BNT162b2: pubmed.ncbi.nlm.nih.gov/34579211/
Biphasic anaphylaxis after first dose of 2019 messenger RNA coronavirus disease vaccine with positive polysorbate 80 skin test result: pubmed.ncbi.nlm.nih.gov/34343674/
#12 Myocardial infarction, stroke, and pulmonary embolism after BNT162b2 mRNA COVID-19 vaccine in persons aged 75 years or older: pubmed.ncbi.nlm.nih.gov/34807248/
A case of acute encephalopathy and non-ST-segment elevation myocardial infarction after vaccination with mRNA-1273: possible adverse effect: pubmed.ncbi.nlm.nih.gov/34703815/
Case report: ANCA-associated vasculitis presenting with rhabdomyolysis and crescentic Pauci-Inmune glomerulonephritis after vaccination with Pfizer-BioNTech COVID-19 mRNA: pubmed.ncbi.nlm.nih.gov/34659268/
Propylthiouracil-induced anti-neutrophil cytoplasmic antibody-associated vasculitis following vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34451967/
Coronavirus disease vaccine 2019 (COVID-19) in systemic lupus erythematosus and neutrophil anti-cytoplasmic antibody-associated vasculitis: pubmed.ncbi.nlm.nih.gov/33928459/
Recurrent herpes zoster after COVID-19 vaccination in patients with chronic urticaria on cyclosporine treatment – A report of 3 cases: pubmed.ncbi.nlm.nih.gov/34510694/
Hypermetabolic lymphadenopathy after administration of BNT162b2 mRNA vaccine Covid-19: incidence assessed by [ 18 F] FDG PET-CT and relevance for study interpretation: pubmed.ncbi.nlm.nih.gov/33774684/
Evolution of bilateral hypermetabolic axillary hypermetabolic lymphadenopathy on FDG PET/CT after 2-dose COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34735411/
Lymphadenopathy associated with COVID-19 vaccination on FDG PET/CT: distinguishing features in adenovirus-vectored vaccine: pubmed.ncbi.nlm.nih.gov/34115709/.
COVID-19 vaccination-induced lymphadenopathy in a specialized breast imaging clinic in Israel: analysis of 163 cases: pubmed.ncbi.nlm.nih.gov/34257025/.
COVID-19 vaccine-related axillary lymphadenopathy in breast cancer patients: case series with literature review: pubmed.ncbi.nlm.nih.gov/34836672/.
Coronavirus disease vaccine 2019 mimics lymph node metastases in patients undergoing skin cancer follow-up: a single-center study: pubmed.ncbi.nlm.nih.gov/34280870/
Regional lymphadenopathy after COVID-19 vaccination: review of the literature and considerations for patient management in breast cancer care: pubmed.ncbi.nlm.nih.gov/34731748/
Subclinical axillary lymphadenopathy associated with COVID-19 vaccination on screening mammography: pubmed.ncbi.nlm.nih.gov/34906409/
Adverse events of COVID injection that may occur in children.Acute-onset supraclavicular lymphadenopathy coincident with intramuscular mRNA vaccination against COVID-19 may be related to the injection technique of the vaccine, Spain, January and February 2021: pubmed.ncbi.nlm.nih.gov/33706861/
Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography: pubmed.ncbi.nlm.nih.gov/34116295/
Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F] choline PET / CT, not just an FDG finding: pubmed.ncbi.nlm.nih.gov/33661328/
Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19: pubmed.ncbi.nlm.nih.gov/34050949/
Axillary adenopathy associated with COVID-19 vaccination: imaging findings and follow-up recommendations in 23 women: pubmed.ncbi.nlm.nih.gov/33624520/
Unique imaging findings of neurologic phantosmia after Pfizer-BioNtech COVID-19 vaccination: a case report: pubmed.ncbi.nlm.nih.gov/34096896/
Thrombotic adverse events reported for Moderna, Pfizer, and Oxford-AstraZeneca COVID-19 vaccines: comparison of occurrence and clinical outcomes in the EudraVigilance database: pubmed.ncbi.nlm.nih.gov/34835256/
Unilateral lymphadenopathy after COVID-19 vaccination: a practical management plan for radiologists of all specialties: pubmed.ncbi.nlm.nih.gov/33713605/
Supraclavicular lymphadenopathy after COVID-19 vaccination: an increasing presentation in the two-week wait neck lump clinic: pubmed.ncbi.nlm.nih.gov/33685772/
COVID-19 vaccine-related axillary and cervical lymphadenopathy in patients with current or previous breast cancer and other...
#13 COVID-19 vaccine-related axillary and cervical lymphadenopathy in patients with current or previous breast cancer and other malignancies: cross-sectional imaging findings on MRI, CT and PET-CT: pubmed.ncbi.nlm.nih.gov/34719892/
COVID-19 vaccination and lower cervical lymphadenopathy in two-week neck lump clinic: a follow-up audit: pubmed.ncbi.nlm.nih.gov/33947605/.
Cervical lymphadenopathy after coronavirus disease vaccination 2019: clinical features and implications for head and neck cancer services: pubmed.ncbi.nlm.nih.gov/34526175/
Systemic capillary extravasation syndrome after vaccination with ChAdOx1 nCOV-19 (Oxford-AstraZeneca): pubmed.ncbi.nlm.nih.gov/34362727/
Unilateral axillary lymphadenopathy related to COVID-19 vaccine: pattern on screening breast MRI allowing benign evaluation: pubmed.ncbi.nlm.nih.gov/34325221/
Acute-onset supraclavicular lymphadenopathy coincident with intramuscular mRNA vaccination against COVID-19 may be related to the injection technique of the vaccine, Spain, January and February 2021: pubmed.ncbi.nlm.nih.gov/33706861/
Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography: pubmed.ncbi.nlm.nih.gov/34116295/
Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F] choline PET / CT, not just an FDG finding: pubmed.ncbi.nlm.nih.gov/33661328/
Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19: pubmed.ncbi.nlm.nih.gov/34050949/
Axillary adenopathy associated with COVID-19 vaccination: imaging findings and follow-up recommendations in 23 women: pubmed.ncbi.nlm.nih.gov/33624520/
Unique imaging findings of neurologic phantosmia after Pfizer-BioNtech COVID-19 vaccination: a case report: pubmed.ncbi.nlm.nih.gov/34096896/
Thrombotic adverse events reported for Moderna, Pfizer, and Oxford-AstraZeneca COVID-19 vaccines: comparison of occurrence and clinical outcomes in the EudraVigilance database: pubmed.ncbi.nlm.nih.gov/34835256/
Unilateral lymphadenopathy after COVID-19 vaccination: a practical management plan for radiologists of all specialties: pubmed.ncbi.nlm.nih.gov/33713605/
Supraclavicular lymphadenopathy after COVID-19 vaccination: an increasing presentation in the two-week wait neck lump clinic: pubmed.ncbi.nlm.nih.gov/33685772/
COVID-19 vaccine-related axillary and cervical lymphadenopathy in patients with current or previous breast cancer and other malignancies: cross-sectional imaging findings on MRI, CT and PET-CT: pubmed.ncbi.nlm.nih.gov/34719892/
COVID-19 vaccination and lower cervical lymphadenopathy in two-week neck lump clinic: a follow-up audit: pubmed.ncbi.nlm.nih.gov/33947605/.
Cervical lymphadenopathy after coronavirus disease vaccination 2019: clinical features and implications for head and neck cancer services: pubmed.ncbi.nlm.nih.gov/34526175/
Systemic capillary extravasation syndrome after vaccination with ChAdOx1 nCOV-19 (Oxford-AstraZeneca): pubmed.ncbi.nlm.nih.gov/34362727/
Unilateral axillary lymphadenopathy related to COVID-19 vaccine: pattern on screening breast MRI allowing benign evaluation: pubmed.ncbi.nlm.nih.gov/34325221/
Abbate, A., Gavin, J., Madanchi, N., Kim, C., Shah, P. R., Klein, K., . . . Danielides, S. (2021). Fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 mRNA COVID-19 vaccination in two patients. Int J Cardiol, 340, 119-121. doi:10.1016/j.ijcard.2021.08.018. www.ncbi.nlm.nih.gov/pubmed/34416319
Abu Mouch, S., Roguin, A., Hellou, E., Ishai, A., Shoshan, U., Mahamid, L., . . . Berar Yanay, N. (2021). Myocarditis following COVID-19 mRNA vaccination. Vaccine, 39(29), 3790-3793. doi:10.1016/j.vaccine.2021.05.087. www.ncbi.nlm.nih.gov/pubmed/34092429
Albert, E., Aurigemma, G., Saucedo, J., & Gerson, D. S. (2021). Myocarditis following COVID-19 vaccination. Radiol Case Rep, 16(8), 2142-2145. doi:10.1016/j.radcr.2021.05.033. www.ncbi.nlm.nih.gov/pubmed/34025885
Aye, Y. N., Mai, A. S., Zhang, A., Lim, O. Z. H., Lin, N., Ng, C. H., . . . Chew, N. W. S. (2021). Acute Myocardial Infarction and Myocarditis following COVID-19 Vaccination. QJM. doi:10.1093/qjmed/hcab252. www.ncbi.nlm.nih.gov/pubmed/34586408
Azir, M., Inman, B., Webb, J., & Tannenbaum, L. (2021). STEMI Mimic: Focal Myocarditis in an Adolescent Patient After mRNA COVID-19 Vaccine. J Emerg Med, 61(6), e129-e132. doi:10.1016/j.jemermed.2021.09.017. www.ncbi.nlm.nih.gov/pubmed/34756746
Barda, N., Dagan, N., Ben-Shlomo, Y., Kepten, E., Waxman, J., Ohana, R., . . . Balicer, R. D. (2021). Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med, 385(12), 1078-1090. doi:10.1056/NEJMoa2110475. www.ncbi.nlm.nih.gov/pubmed/34432976
Bhandari, M., Pradhan, A., Vishwakarma, P., & Sethi, R. (2021). Coronavirus and cardiovascular manifestations- getting to the heart of the matter. World J Cardiol, 13(10), 556-565. doi:10.4330/wjc.v13.i10.556. www.ncbi.nlm.nih.gov/pubmed/34754400
Bozkurt, B., Kamat, I., & Hotez, P. J. (2021). Myocarditis With COVID-19 mRNA Vaccines. Circulation, 144(6), 471-484. doi:10.1161/CIRCULATIONAHA.121.056135. www.ncbi.nlm.nih.gov/pubmed/34281357
Buchhorn, R., Meyer, C., Schulze-Forster, K., Junker, J., & Heidecke, H. (2021). Autoantibody Release in Children after Corona Virus mRNA Vaccination: A Risk Factor of Multisystem Inflammatory Syndrome? Vaccines (Basel), 9(11). doi:10.3390/vaccines9111353. www.ncbi.nlm.nih.gov/pubmed/34835284
Calcaterra, G., Bassareo, P. P., Barilla, F., Romeo, F., & Mehta, J. L. (2022). Concerning the unexpected prothrombotic state following some coronavirus disease 2019 vaccines. J Cardiovasc Med (Hagerstown), 23(2), 71-74. doi:10.2459/JCM.0000000000001232. www.ncbi.nlm.nih.gov/pubmed/34366403
Calcaterra, G., Mehta, J. L., de Gregorio, C., Butera, G., Neroni, P., Fanos, V., & Bassareo, P. P. (2021). COVID 19 Vaccine for Adolescents. Concern about Myocarditis and Pericarditis. Pediatr Rep, 13(3), 530-533. doi:10.3390/pediatric13030061. www.ncbi.nlm.nih.gov/pubmed/34564344
Chai, Q., Nygaard, U., Schmidt, R. C., Zaremba, T., Moller, A. M., & Thorvig, C. M. (2022). Multisystem inflammatory syndrome in a male adolescent after his second Pfizer-BioNTech COVID-19 vaccine. Acta Paediatr...
#14 Chai, Q., Nygaard, U., Schmidt, R. C., Zaremba, T., Moller, A. M., & Thorvig, C. M. (2022). Multisystem inflammatory syndrome in a male adolescent after his second Pfizer-BioNTech COVID-19 vaccine. Acta Paediatr, 111(1), 125-127. doi:10.1111/apa.16141. www.ncbi.nlm.nih.gov/pubmed/34617315
Chamling, B., Vehof, V., Drakos, S., Weil, M., Stalling, P., Vahlhaus, C., . . . Yilmaz, A. (2021). Occurrence of acute infarct-like myocarditis following COVID-19 vaccination: just an accidental co-incidence or rather vaccination-associated autoimmune myocarditis? Clin Res Cardiol, 110(11), 1850-1854. doi:10.1007/s00392-021-01916-w. www.ncbi.nlm.nih.gov/pubmed/34333695
Chang, J. C., & Hawley, H. B. (2021). Vaccine-Associated Thrombocytopenia and Thrombosis: Venous Endotheliopathy Leading to Venous Combined Micro-Macrothrombosis. Medicina (Kaunas), 57(11). doi:10.3390/medicina57111163. www.ncbi.nlm.nih.gov/pubmed/34833382
Chelala, L., Jeudy, J., Hossain, R., Rosenthal, G., Pietris, N., & White, C. (2021). Cardiac MRI Findings of Myocarditis After COVID-19 mRNA Vaccination in Adolescents. AJR Am J Roentgenol. doi:10.2214/AJR.21.26853. www.ncbi.nlm.nih.gov/pubmed/34704459
Choi, S., Lee, S., Seo, J. W., Kim, M. J., Jeon, Y. H., Park, J. H., . . . Yeo, N. S. (2021). Myocarditis-induced Sudden Death after BNT162b2 mRNA COVID-19 Vaccination in Korea: Case Report Focusing on Histopathological Findings. J Korean Med Sci, 36(40), e286. doi:10.3346/jkms.2021.36.e286. www.ncbi.nlm.nih.gov/pubmed/34664804
Chouchana, L., Blet, A., Al-Khalaf, M., Kafil, T. S., Nair, G., Robblee, J., . . . Liu, P. P. (2021). Features of Inflammatory Heart Reactions Following mRNA COVID-19 Vaccination at a Global Level. Clin Pharmacol Ther. doi:10.1002/cpt.2499. www.ncbi.nlm.nih.gov/pubmed/34860360
Chua, G. T., Kwan, M. Y. W., Chui, C. S. L., Smith, R. D., Cheung, E. C., Tian, T., . . . Ip, P. (2021). Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination. Clin Infect Dis. doi:10.1093/cid/ciab989. www.ncbi.nlm.nih.gov/pubmed/34849657
Clarke, R., & Ioannou, A. (2021). Should T2 mapping be used in cases of recurrent myocarditis to differentiate between the acute inflammation and chronic scar? J Pediatr. doi:10.1016/j.jpeds.2021.12.026. www.ncbi.nlm.nih.gov/pubmed/34933012
Colaneri, M., De Filippo, M., Licari, A., Marseglia, A., Maiocchi, L., Ricciardi, A., . . . Bruno, R. (2021). COVID vaccination and asthma exacerbation: might there be a link? Int J Infect Dis, 112, 243-246. doi:10.1016/j.ijid.2021.09.026. www.ncbi.nlm.nih.gov/pubmed/34547487
Das, B. B., Kohli, U., Ramachandran, P., Nguyen, H. H., Greil, G., Hussain, T., . . . Khan, D. (2021). Myopericarditis after messenger RNA Coronavirus Disease 2019 Vaccination in Adolescents 12 to 18 Years of Age. J Pediatr, 238, 26-32 e21. doi:10.1016/j.jpeds.2021.07.044. www.ncbi.nlm.nih.gov/pubmed/34339728
Das, B. B., Moskowitz, W. B., Taylor, M. B., & Palmer, A. (2021). Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination: What Do We Know So Far? Children (Basel), 8(7). doi:10.3390/children8070607. www.ncbi.nlm.nih.gov/pubmed/34356586
Deb, A., Abdelmalek, J., Iwuji, K., & Nugent, K. (2021). Acute Myocardial Injury Following COVID-19 Vaccination: A Case Report and Review of Current Evidence from Vaccine Adverse Events Reporting System Database. J Prim Care Community Health, 12, 21501327211029230. doi:10.1177/21501327211029230. www.ncbi.nlm.nih.gov/pubmed/34219532
Dickey, J. B., Albert, E., Badr, M., Laraja, K. M., Sena, L. M., Gerson, D. S., . . . Aurigemma, G. P. (2021). A Series of Patients With Myocarditis Following SARS-CoV-2 Vaccination With mRNA-1279 and BNT162b2. JACC Cardiovasc Imaging, 14(9), 1862-1863. doi:10.1016/j.jcmg.2021.06.003. www.ncbi.nlm.nih.gov/pubmed/34246585
Dimopoulou, D., Spyridis, N., Vartzelis, G., Tsolia, M. N., & Maritsi, D. N. (2021). Safety and tolerability of the COVID-19 mRNA-vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF-inhibitors. Arthritis Rheumatol. doi:10.1002/art.41977. www.ncbi.nlm.nih.gov/pubmed/34492161
Dimopoulou, D., Vartzelis, G., Dasoula, F., Tsolia, M., & Maritsi, D. (2021). Immunogenicity of the COVID-19 mRNA vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF inhibitors. Ann Rheum Dis. doi:10.1136/annrheumdis-2021-221607. www.ncbi.nlm.nih.gov/pubmed/34844930
Ehrlich, P., Klingel, K., Ohlmann-Knafo, S., Huttinger, S., Sood, N., Pickuth, D., & Kindermann, M. (2021). Biopsy-proven lymphocytic myocarditis following first mRNA COVID-19 vaccination in a 40-year-old male: case report. Clin Res Cardiol, 110(11), 1855-1859. doi:10.1007/s00392-021-01936-6. www.ncbi.nlm.nih.gov/pubmed/34487236
El Sahly, H. M., Baden, L. R., Essink, B., Doblecki-Lewis, S., Martin, J. M., Anderson, E. J., . . . Group, C. S. (2021). Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N Engl J Med, 385(19), 1774-1785. doi:10.1056/NEJMoa2113017. www.ncbi.nlm.nih.gov/pubmed/34551225
Facetti, S., Giraldi, M., Vecchi, A. L., Rogiani, S., & Nassiacos, D. (2021). [Acute myocarditis in a young adult two days after Pfizer vaccination]. G Ital Cardiol (Rome), 22(11), 891-893. doi:10.1714/3689.36746. www.ncbi.nlm.nih.gov/pubmed/34709227
Fazlollahi, A., Zahmatyar, M., Noori, M., Nejadghaderi, S. A., Sullman, M. J. M., Shekarriz-Foumani, R., . . . Safiri, S. (2021). Cardiac complications following mRNA COVID-19 vaccines: A systematic review of case reports and case series. Rev Med Virol, e2318. doi:10.1002/rmv.2318. www.ncbi.nlm.nih.gov/pubmed/34921468
Fazolo, T., Lima, K., Fontoura, J. C., de Souza, P. O., Hilario, G., Zorzetto, R., . . . Bonorino, C. (2021). Pediatric COVID-19 patients in South Brazil show abundant viral mRNA and strong specific anti-viral responses. Nat Commun, 12(1), 6844. doi:10.1038/s41467-021-27120-y. www.ncbi.nlm.nih.gov/pubmed/34824230
Fikenzer, S., & Laufs, U. (2021). Correction to: Response to Letter to the editors referring to Fikenzer, S., Uhe, T., Lavall, D., Rudolph, U., Falz, R., Busse, M., Hepp, P., & Laufs, U. (2020). Effects of surgical and FFP2/N95 face masks on cardiopulmonary exercise capacity. Clinical research in cardiology: official journal of the German Cardiac Society, 1-9. Advance online publication. doi.org/10.1007/s00392-020-01704-y. Clin Res Cardiol, 110(8), 1352. doi:10.1007/s00392-021-01896-x. www.ncbi.nlm.nih.gov/pubmed/34170372
Foltran, D., Delmas, C., Flumian, C., De Paoli, P., Salvo, F., Gautier, S., . . . Montastruc, F. (2021). Myocarditis and Pericarditis in Adolescents after First and Second doses of mRNA COVID-19 Vaccines. Eur Heart J Qual Care Clin Outcomes. doi:10.1093/ehjqcco/qcab090. www.ncbi.nlm.nih.gov/pubmed/34849667
Forgacs, D., Jang, H., Abreu, R. B., Hanley, H. B., Gattiker, J. L., Jefferson, A. M., & Ross, T. M. (2021). SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naive and Pre-Immune Humans. Front Immunol, 12, 728021. doi:10.3389/fimmu.2021.728021. www.ncbi.nlm.nih.gov/pubmed/34646267
Furer, V., Eviatar, T., Zisman, D., Peleg, H., Paran, D., Levartovsky, D., . . . Elkayam, O. (2021). Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis, 80(10), 1330-1338. doi:10.1136/annrheumdis-2021-220647. www.ncbi.nlm.nih.gov/pubmed/34127481
Galindo, R., Chow, H., & Rongkavilit, C. (2021). COVID-19 in Children: Clinical Manifestations and Pharmacologic Interventions Including Vaccine Trials. Pediatr Clin North Am, 68(5), 961-976. doi:10.1016/j.pcl.2021.05.004. www.ncbi.nlm.nih.gov/pubmed/34538306
Gargano, J. W., Wallace, M., Hadler, S. C., Langley, G., Su, J. R., Oster, M. E., . . . Oliver, S. E. (2021). Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices – United States, June 2021. MMWR Morb Mortal Wkly Rep, 70(27), 977-982. doi:10.15585/mmwr.mm7027e2. www.ncbi.nlm.nih.gov/pubmed/34237049
Gatti, M., Raschi, E., Moretti, U., Ardizzoni, A., Poluzzi, E., & Diemberger, I. (2021). Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase. Vaccines (Basel), 9(1). doi:10.3390/vaccines9010019. www.ncbi.nlm.nih.gov/pubmed/33406694
Gautam, N., Saluja, P., Fudim, M., Jambhekar, K., Pandey, T., & Al’Aref, S. (2021). A Late Presentation of COVID-19 Vaccine-Induced Myocarditis. Cureus, 13(9), e17890. doi:10.7759/cureus.17890. www.ncbi.nlm.nih.gov/pubmed/34660088
Gellad, W. F. (2021). Myocarditis after vaccination against covid-19. BMJ, 375, n3090. doi:10.1136/bmj.n3090. www.ncbi.nlm.nih.gov/pubmed/34916217
Greenhawt, M., Abrams, E. M., Shaker, M., Chu, D. K., Khan, D., Akin, C., . . . Golden, D. B. K. (2021). The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach. J Allergy Clin Immunol Pract, 9(10), 3546-3567. doi:10.1016/j.jaip.2021.06.006. www.ncbi.nlm.nih.gov/pubmed/34153517
Haaf, P., Kuster, G. M., Mueller, C., Berger, C. T., Monney, P., Burger, P., . . . Tanner, F. C. (2021). The very low risk of myocarditis and pericarditis after mRNA COVID-19 vaccination should not discourage vaccination. Swiss Med Wkly, 151, w30087. doi:10.4414/smw.2021.w30087. www.ncbi.nlm.nih.gov/pubmed/34668687
Hasnie, A. A., Hasnie, U. A., Patel, N., Aziz, M. U., Xie, M., Lloyd, S. G., & Prabhu, S. D. (2021). Perimyocarditis...
#15 Hasnie, A. A., Hasnie, U. A., Patel, N., Aziz, M. U., Xie, M., Lloyd, S. G., & Prabhu, S. D. (2021). Perimyocarditis following first dose of the mRNA-1273 SARS-CoV-2 (Moderna) vaccine in a healthy young male: a case report. BMC Cardiovasc Disord, 21(1), 375. doi:10.1186/s12872-021-02183-3. www.ncbi.nlm.nih.gov/pubmed/34348657
Hause, A. M., Gee, J., Baggs, J., Abara, W. E., Marquez, P., Thompson, D., . . . Shay, D. K. (2021). COVID-19 Vaccine Safety in Adolescents Aged 12-17 Years – United States, December 14, 2020-July 16, 2021. MMWR Morb Mortal Wkly Rep, 70(31), 1053-1058. doi:10.15585/mmwr.mm7031e1. www.ncbi.nlm.nih.gov/pubmed/34351881
Helms, J. M., Ansteatt, K. T., Roberts, J. C., Kamatam, S., Foong, K. S., Labayog, J. S., & Tarantino, M. D. (2021). Severe, Refractory Immune Thrombocytopenia Occurring After SARS-CoV-2 Vaccine. J Blood Med, 12, 221-224. doi:10.2147/JBM.S307047. www.ncbi.nlm.nih.gov/pubmed/33854395
Hippisley-Cox, J., Patone, M., Mei, X. W., Saatci, D., Dixon, S., Khunti, K., . . . Coupland, C. A. C. (2021). Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. BMJ, 374, n1931. doi:10.1136/bmj.n1931. www.ncbi.nlm.nih.gov/pubmed/34446426
Ho, J. S., Sia, C. H., Ngiam, J. N., Loh, P. H., Chew, N. W., Kong, W. K., & Poh, K. K. (2021). A review of COVID-19 vaccination and the reported cardiac manifestations. Singapore Med J. doi:10.11622/smedj.2021210. www.ncbi.nlm.nih.gov/pubmed/34808708
Iguchi, T., Umeda, H., Kojima, M., Kanno, Y., Tanaka, Y., Kinoshita, N., & Sato, D. (2021). Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report. Drug Saf, 44(11), 1209-1214. doi:10.1007/s40264-021-01104-9. www.ncbi.nlm.nih.gov/pubmed/34347278
Ioannou, A. (2021a). Myocarditis should be considered in those with a troponin rise and unobstructed coronary arteries following Pfizer-BioNTech COVID-19 vaccination. QJM. doi:10.1093/qjmed/hcab231. www.ncbi.nlm.nih.gov/pubmed/34463755
Ioannou, A. (2021b). T2 mapping should be utilised in cases of suspected myocarditis to confirm an acute inflammatory process. QJM. doi:10.1093/qjmed/hcab326. www.ncbi.nlm.nih.gov/pubmed/34931681
Isaak, A., Feisst, A., & Luetkens, J. A. (2021). Myocarditis Following COVID-19 Vaccination. Radiology, 301(1), E378-E379. doi:10.1148/radiol.2021211766. www.ncbi.nlm.nih.gov/pubmed/34342500
Istampoulouoglou, I., Dimitriou, G., Spani, S., Christ, A., Zimmermanns, B., Koechlin, S., . . . Leuppi-Taegtmeyer, A. B. (2021). Myocarditis and pericarditis in association with COVID-19 mRNA-vaccination: cases from a regional pharmacovigilance centre. Glob Cardiol Sci Pract, 2021(3), e202118. doi:10.21542/gcsp.2021.18. www.ncbi.nlm.nih.gov/pubmed/34805376
Jaafar, R., Boschi, C., Aherfi, S., Bancod, A., Le Bideau, M., Edouard, S., . . . La Scola, B. (2021). High Individual Heterogeneity of Neutralizing Activities against the Original Strain and Nine Different Variants of SARS-CoV-2. Viruses, 13(11). doi:10.3390/v13112177. www.ncbi.nlm.nih.gov/pubmed/34834983
Jain, S. S., Steele, J. M., Fonseca, B., Huang, S., Shah, S., Maskatia, S. A., . . . Grosse-Wortmann, L. (2021). COVID-19 Vaccination-Associated Myocarditis in Adolescents. Pediatrics, 148(5). doi:10.1542/peds.2021-053427. www.ncbi.nlm.nih.gov/pubmed/34389692
Jhaveri, R., Adler-Shohet, F. C., Blyth, C. C., Chiotos, K., Gerber, J. S., Green, M., . . . Zaoutis, T. (2021). Weighing the Risks of Perimyocarditis With the Benefits of SARS-CoV-2 mRNA Vaccination in Adolescents. J Pediatric Infect Dis Soc, 10(10), 937-939. doi:10.1093/jpids/piab061. www.ncbi.nlm.nih.gov/pubmed/34270752
Kaneta, K., Yokoi, K., Jojima, K., Kotooka, N., & Node, K. (2021). Young Male With Myocarditis Following mRNA-1273 Vaccination Against Coronavirus Disease-2019 (COVID-19). Circ J. doi:10.1253/circj.CJ-21-0818. www.ncbi.nlm.nih.gov/pubmed/34744118
Kaul, R., Sreenivasan, J., Goel, A., Malik, A., Bandyopadhyay, D., Jin, C., . . . Panza, J. A. (2021). Myocarditis following COVID-19 vaccination. Int J Cardiol Heart Vasc, 36, 100872. doi:10.1016/j.ijcha.2021.100872. www.ncbi.nlm.nih.gov/pubmed/34568540
Khogali, F., & Abdelrahman, R. (2021). Unusual Presentation of Acute Perimyocarditis Following SARS-COV-2 mRNA-1237 Moderna Vaccination. Cureus, 13(7), e16590. doi:10.7759/cureus.16590. www.ncbi.nlm.nih.gov/pubmed/34447639
Kim, H. W., Jenista, E. R., Wendell, D. C., Azevedo, C. F., Campbell, M. J., Darty, S. N., . . . Kim, R. J. (2021). Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination. JAMA Cardiol, 6(10), 1196-1201. doi:10.1001/jamacardio.2021.2828. www.ncbi.nlm.nih.gov/pubmed/34185046
Kim, I. C., Kim, H., Lee, H. J., Kim, J. Y., & Kim, J. Y. (2021). Cardiac Imaging of Acute Myocarditis Following COVID-19 mRNA Vaccination. J Korean Med Sci, 36(32), e229. doi:10.3346/jkms.2021.36.e229. www.ncbi.nlm.nih.gov/pubmed/34402228
King, W. W., Petersen, M. R., Matar, R. M., Budweg, J. B., Cuervo Pardo, L., & Petersen, J. W. (2021). Myocarditis following mRNA vaccination against SARS-CoV-2, a case series. Am Heart J Plus, 8, 100042. doi:10.1016/j.ahjo.2021.100042. www.ncbi.nlm.nih.gov/pubmed/34396358
Klein, N. P., Lewis, N., Goddard, K., Fireman, B., Zerbo, O., Hanson, K. E., . . . Weintraub, E. S. (2021). Surveillance for Adverse Events After COVID-19 mRNA Vaccination. JAMA, 326(14), 1390-1399. doi:10.1001/jama.2021.15072. www.ncbi.nlm.nih.gov/pubmed/34477808
Klimek, L., Bergmann, K. C., Brehler, R., Pfutzner, W., Zuberbier, T., Hartmann, K., . . . Worm, M. (2021). Practical handling of allergic reactions to COVID-19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and OGAI. Allergo J Int, 1-17. doi:10.1007/s40629-021-00165-7. www.ncbi.nlm.nih.gov/pubmed/33898162
Klimek, L., Novak, N., Hamelmann, E., Werfel, T., Wagenmann, M., Taube, C., . . . Worm, M. (2021). Severe allergic reactions after COVID-19 vaccination with the Pfizer/BioNTech vaccine in Great Britain and USA: Position statement of the German Allergy Societies: Medical Association of German Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA). Allergo J Int, 30(2), 51-55. doi:10.1007/s40629-020-00160-4. www.ncbi.nlm.nih.gov/pubmed/33643776
Kohli, U., Desai, L., Chowdhury, D., Harahsheh, A. S., Yonts, A. B., Ansong, A., . . . Ang, J. Y. (2021). mRNA Coronavirus-19 Vaccine-Associated Myopericarditis in Adolescents: A Survey Study. J Pediatr. doi:10.1016/j.jpeds.2021.12.025. www.ncbi.nlm.nih.gov/pubmed/34952008
Kostoff, R. N., Calina, D., Kanduc, D., Briggs, M. B., Vlachoyiannopoulos, P., Svistunov, A. A., & Tsatsakis, A. (2021a). Erratum to “Why are we vaccinating children against COVID-19?” [Toxicol. Rep. 8C (2021) 1665-1684 / 1193]. Toxicol Rep, 8, 1981. doi:10.1016/j.toxrep.2021.10.003. www.ncbi.nlm.nih.gov/pubmed/34642628
Kostoff, R. N., Calina, D., Kanduc, D., Briggs, M. B., Vlachoyiannopoulos, P., Svistunov, A. A., & Tsatsakis, A. (2021b). Why are we vaccinating children against COVID-19? Toxicol Rep, 8, 1665-1684. doi:10.1016/j.toxrep.2021.08.010. www.ncbi.nlm.nih.gov/pubmed/34540594
Kremsner, P. G., Mann, P., Kroidl, A., Leroux-Roels, I., Schindler, C., Gabor, J. J., . . . Group, C.-N.-S. (2021). Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : A phase 1 randomized clinical trial. Wien Klin Wochenschr, 133(17-18), 931-941. doi:10.1007/s00508-021-01922-y. www.ncbi.nlm.nih.gov/pubmed/34378087
Kustin, T., Harel, N., Finkel, U., Perchik, S., Harari, S., Tahor, M., . . . Stern, A. (2021). Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. Nat Med, 27(8), 1379-1384. doi:10.1038/s41591-021-01413-7. www.ncbi.nlm.nih.gov/pubmed/34127854
Kwan, M. Y. W., Chua, G. T., Chow, C. B., Tsao, S. S. L., To, K. K. W., Yuen, K. Y., . . . Ip, P. (2021). mRNA COVID vaccine and myocarditis in adolescents. Hong Kong Med J, 27(5), 326-327. doi:10.12809/hkmj215120. www.ncbi.nlm.nih.gov/pubmed/34393110
Lee, E., Chew, N. W. S., Ng, P., & Yeo, T. J. (2021). Reply to “Letter to the editor: Myocarditis should be considered in those with a troponin rise and unobstructed coronary arteries following PfizerBioNTech COVID-19 vaccination”. QJM. doi:10.1093/qjmed/hcab232. www.ncbi.nlm.nih.gov/pubmed/34463770
Lee, E. J., Cines, D. B., Gernsheimer, T., Kessler, C., Michel, M., Tarantino, M. D., . . . Bussel, J. B. (2021). Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. Am J Hematol, 96(5), 534-537. doi:10.1002/ajh.26132. www.ncbi.nlm.nih.gov/pubmed/33606296
Levin, D., Shimon, G., Fadlon-Derai, M., Gershovitz, L., Shovali, A., Sebbag, A., . . . Gordon, B. (2021). Myocarditis following COVID-19 vaccination – A case series. Vaccine, 39(42), 6195-6200. doi:10.1016/j.vaccine.2021.09.004. www.ncbi.nlm.nih.gov/pubmed/34535317
Li, J., Hui, A., Zhang, X., Yang, Y., Tang, R., Ye, H., . . . Zhu, F. (2021). Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study. Nat Med, 27(6), 1062-1070. doi:10.1038/s41591-021-01330-9. www.ncbi.nlm.nih.gov/pubmed/33888900
Li, M., Yuan, J., Lv, G., Brown, J., Jiang, X., & Lu, Z. K. (2021). Myocarditis and Pericarditis following...
0k 16
Hemos deshabilitado la autenticación con Facebook. Si entras a Mediatize con una cuenta de Facebook, lee esto.
*
Reporting of acute inflammatory neuropathies with COVID-19 vaccines: subgroup disproportionality analysis in VigiBase: pubmed.ncbi.nlm.nih.gov/34579259/
A variant of Guillain-Barré syndrome after SARS-CoV-2 vaccination: AMSAN: pubmed.ncbi.nlm.nih.gov/34370408/.
A rare variant of Guillain-Barré syndrome after vaccination with Ad26.COV2.S: pubmed.ncbi.nlm.nih.gov/34703690/.
Guillain-Barré syndrome after SARS-CoV-2 vaccination in a patient with previous vaccine-associated Guillain-Barré syndrome: pubmed.ncbi.nlm.nih.gov/34810163/
Guillain-Barré syndrome in an Australian state using mRNA and adenovirus-vector SARS-CoV-2 vaccines: onlinelibrary.wiley.com/doi/10.1002/ana.26218.
Acute transverse myelitis after SARS-CoV-2 vaccination: case report and review of the literature: pubmed.ncbi.nlm.nih.gov/34482455/.
Variant Guillain-Barré syndrome occurring after SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34114269/.
Guillian-Barre syndrome with axonal variant temporally associated with Modern SARS-CoV-2 mRNA-based vaccine: pubmed.ncbi.nlm.nih.gov/34722067/
Guillain-Barre syndrome after the first dose of SARS-CoV-2 vaccine: a temporary occurrence, not a causal association: pubmed.ncbi.nlm.nih.gov/33968610/
SARS-CoV-2 vaccines can be complicated not only by Guillain-Barré syndrome but also by distal small fiber neuropathy: pubmed.ncbi.nlm.nih.gov/34525410/
Clinical variant of Guillain-Barré syndrome with prominent facial diplegia after AstraZeneca 2019 coronavirus disease vaccine: pubmed.ncbi.nlm.nih.gov/34808658/
Adverse event reporting and risk of Bell’s palsy after COVID-19 vaccination: www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00646-0/ful.
Bilateral facial nerve palsy and COVID-19 vaccination: causality or coincidence: pubmed.ncbi.nlm.nih.gov/34522557/
Left Bell’s palsy after the first dose of mRNA-1273 SARS-CoV-2 vaccine: case report: pubmed.ncbi.nlm.nih.gov/34763263/.
Bell’s palsy after inactivated vaccination with COVID-19 in a patient with a history of recurrent Bell’s palsy: case report: pubmed.ncbi.nlm.nih.gov/34621891/
Neurological complications after the first dose of COVID-19 vaccines and SARS-CoV-2 infection: pubmed.ncbi.nlm.nih.gov/34697502/
Type I interferons as a potential mechanism linking COVID-19 mRNA vaccines with Bell’s palsy: pubmed.ncbi.nlm.nih.gov/33858693/
Acute transverse myelitis following inactivated COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34370410/
Acute transverse myelitis after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34579245/.
A case of longitudinally extensive transverse myelitis following Covid-19 vaccination: pubmed.ncbi.nlm.nih.gov/34182207/
Post COVID-19 transverse myelitis; a case report with review of the literature: pubmed.ncbi.nlm.nih.gov/34457267/.
Beware of neuromyelitis optica spectrum disorder after vaccination with inactivated virus for COVID-19: pubmed.ncbi.nlm.nih.gov/34189662/
Neuromyelitis optica in a healthy woman after vaccination against severe acute respiratory syndrome coronavirus 2 mRNA-1273: pubmed.ncbi.nlm.nih.gov/34660149/
Acute bilateral bilateral optic neuritis/chiasm with longitudinal extensive transverse myelitis in long-standing stable multiple sclerosis after vector-based vaccination against SARS-CoV-2: pubmed.ncbi.nlm.nih.gov/34131771/
A case series of acute pericarditis after vaccination with COVID-19 in the context of recent reports from Europe and the United States: pubmed.ncbi.nlm.nih.gov/34635376/
Acute pericarditis and cardiac tamponade after vaccination with Covid-19: pubmed.ncbi.nlm.nih.gov/34749492/
Myocarditis and pericarditis in adolescents after the first and second doses of COVID-19 mRNA vaccines: pubmed.ncbi.nlm.nih.gov/34849667/
Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34319393/
Acute myopericarditis after COVID-19 vaccine in adolescents: pubmed.ncbi.nlm.nih.gov/34589238/
Pericarditis after administration of the BNT162b2 mRNA vaccine COVID-19: pubmed.ncbi.nlm.nih.gov/34149145/
Case report: symptomatic pericarditis post COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34693198/.
An outbreak of Still’s disease after COVID-19 vaccination in a 34-year-old patient: pubmed.ncbi.nlm.nih.gov/34797392/
Hemophagocytic lymphohistiocytosis following COVID-19 vaccination (ChAdOx1 nCoV-19): pubmed.ncbi.nlm.nih.gov/34862234/
Myocarditis after SARS-CoV-2 mRNA vaccination, a case series: pubmed.ncbi.nlm.nih.gov/34396358/.
Miller-Fisher syndrome and Guillain-Barré syndrome overlap syndrome in a patient after Oxford-AstraZeneca SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34848426/.
Immune-mediated disease outbreaks or new-onset disease in 27 subjects after mRNA/DNA vaccination against SARS-CoV-2: pubmed.ncbi.nlm.nih.gov/33946748/
Post-mortem investigation of deaths after vaccination with COVID-19 vaccines: pubmed.ncbi.nlm.nih.gov/34591186/
Acute kidney injury with macroscopic hematuria and IgA nephropathy after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34352309/
Relapse of immune thrombocytopenia after covid-19 vaccination in young male patient: pubmed.ncbi.nlm.nih.gov/34804803/.
Immune thrombocytopenic purpura associated with COVID-19 mRNA vaccine Pfizer-BioNTech BNT16B2b2: pubmed.ncbi.nlm.nih.gov/34077572/
Retinal hemorrhage after SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34884407/.
Case report: anti-neutrophil cytoplasmic antibody-associated vasculitis with acute renal failure and pulmonary hemorrhage can occur after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34859017/
Intracerebral hemorrhage due to vasculitis following COVID-19 vaccination: case report: pubmed.ncbi.nlm.nih.gov/34783899/
Peduncular, symptomatic cavernous bleeding after immune thrombocytopenia-induced SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34549178/.
Brain death in a vaccinated patient with COVID-19 infection: pubmed.ncbi.nlm.nih.gov/34656887/
Generalized purpura annularis telangiectodes after SARS-CoV-2 mRNA vaccination: pubmed.ncbi.nlm.nih.gov/34236717/.
Lobar hemorrhage with ventricular rupture shortly after the first dose of a SARS-CoV-2 mRNA-based SARS-CoV-2 vaccine: pubmed.ncbi.nlm.nih.gov/34729467/.
A case of outbreak of macroscopic hematuria and IgA nephropathy after SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/33932458/
Acral hemorrhage after administration of the second dose of SARS-CoV-2 vaccine. A post-vaccination reaction: pubmed.ncbi.nlm.nih.gov/34092400/742.
Severe immune thrombocytopenic purpura after SARS-CoV-2 vaccine: pubmed.ncbi.nlm.nih.gov/34754937/
Gross hematuria after severe acute respiratory syndrome coronavirus 2 vaccination in 2 patients with IgA nephropathy: pubmed.ncbi.nlm.nih.gov/33771584/
Autoimmune encephalitis after ChAdOx1-S SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34846583/
COVID-19 vaccine and death: causality algorithm according to the WHO eligibility diagnosis: pubmed.ncbi.nlm.nih.gov/34073536/
Bell’s palsy after vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and a nested case-control study: pubmed.ncbi.nlm.nih.gov/34411532/
Epidemiology of myocarditis and pericarditis following mRNA vaccines in Ontario, Canada: by vaccine product, schedule, and interval: www.medrxiv.org/content/10.1101/2021.12.02.21267156v1
Anaphylaxis following Covid-19 vaccine in a patient with cholinergic urticaria: pubmed.ncbi.nlm.nih.gov/33851711/
Anaphylaxis induced by CoronaVac COVID-19 vaccine: clinical features and results of revaccination: pubmed.ncbi.nlm.nih.gov/34675550/.
Anaphylaxis after Modern COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34734159/.
Association of self-reported history of high-risk allergy with allergy symptoms after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34698847/
Sex differences in the incidence of anaphylaxis to LNP-mRNA vaccines COVID-19: pubmed.ncbi.nlm.nih.gov/34020815/
Allergic reactions, including anaphylaxis, after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine – United States, December 14 to 23, 2020: pubmed.ncbi.nlm.nih.gov/33641264/
Allergic reactions, including anaphylaxis, after receiving the first dose of Modern COVID-19 vaccine – United States, December 21, 2020 to January 10, 2021: pubmed.ncbi.nlm.nih.gov/33641268/
Prolonged anaphylaxis to Pfizer 2019 coronavirus disease vaccine: a case report and mechanism of action: pubmed.ncbi.nlm.nih.gov/33834172/
Anaphylaxis reactions to Pfizer BNT162b2 vaccine: report of 3 cases of anaphylaxis following vaccination with Pfizer BNT162b2: pubmed.ncbi.nlm.nih.gov/34579211/
Biphasic anaphylaxis after first dose of 2019 messenger RNA coronavirus disease vaccine with positive polysorbate 80 skin test result: pubmed.ncbi.nlm.nih.gov/34343674/
Acute myocardial infarction and myocarditis after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34586408/
Takotsubo syndrome after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34539938/.
Takotsubo cardiomyopathy after coronavirus 2019 vaccination in patient on maintenance hemodialysis: pubmed.ncbi.nlm.nih.gov/34731486/.
Premature myocardial infarction or side effect of COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/33824804/
Myocardial infarction, stroke, and pulmonary embolism...
*
Kounis syndrome type 1 induced by inactivated SARS-COV-2 vaccine: pubmed.ncbi.nlm.nih.gov/34148772/
Acute myocardial infarction within 24 hours after COVID-19 vaccination: is Kounis syndrome the culprit: pubmed.ncbi.nlm.nih.gov/34702550/
Deaths associated with the recently launched SARS-CoV-2 vaccination (Comirnaty
Deaths associated with recently launched SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34425384/
A case of acute encephalopathy and non-ST-segment elevation myocardial infarction after vaccination with mRNA-1273: possible adverse effect: pubmed.ncbi.nlm.nih.gov/34703815/
COVID-19 vaccine-induced urticarial vasculitis: pubmed.ncbi.nlm.nih.gov/34369046/.
ANCA-associated vasculitis after Pfizer-BioNTech COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34280507/.
New-onset leukocytoclastic vasculitis after COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34241833/
Cutaneous small vessel vasculitis after COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34529877/.
Outbreak of leukocytoclastic vasculitis after COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/33928638/
Leukocytoclastic vasculitis after exposure to COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34836739/
Vasculitis and bursitis in [ 18 F] FDG-PET/CT after COVID-19 mRNA vaccine: post hoc ergo propter hoc?; pubmed.ncbi.nlm.nih.gov/34495381/.
Cutaneous lymphocytic vasculitis after administration of COVID-19 mRNA vaccine: pubmed.ncbi.nlm.nih.gov/34327795
Cutaneous leukocytoclastic vasculitis induced by Sinovac COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34660867/.
Case report: ANCA-associated vasculitis presenting with rhabdomyolysis and crescentic Pauci-Inmune glomerulonephritis after vaccination with Pfizer-BioNTech COVID-19 mRNA: pubmed.ncbi.nlm.nih.gov/34659268/
Reactivation of IgA vasculitis after vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34848431/
Varicella-zoster virus-related small-vessel vasculitis after Pfizer-BioNTech COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34310759/.
Imaging in vascular medicine: leukocytoclastic vasculitis after COVID-19 vaccine booster: pubmed.ncbi.nlm.nih.gov/34720009/
A rare case of Henoch-Schönlein purpura after a case report of COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34518812/
Cutaneous vasculitis following COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34611627/.
Possible case of COVID-19 mRNA vaccine-induced small-vessel vasculitis: pubmed.ncbi.nlm.nih.gov/34705320/.
IgA vasculitis following COVID-19 vaccination in an adult: pubmed.ncbi.nlm.nih.gov/34779011/
Propylthiouracil-induced anti-neutrophil cytoplasmic antibody-associated vasculitis following vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34451967/
Coronavirus disease vaccine 2019 (COVID-19) in systemic lupus erythematosus and neutrophil anti-cytoplasmic antibody-associated vasculitis: pubmed.ncbi.nlm.nih.gov/33928459/
Reactivation of IgA vasculitis after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34250509/
Clinical and histopathologic spectrum of delayed adverse skin reactions after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34292611/.
First description of immune complex vasculitis after COVID-19 vaccination with BNT162b2: case report: pubmed.ncbi.nlm.nih.gov/34530771/.
Nephrotic syndrome and vasculitis after SARS-CoV-2 vaccine: true association or circumstantial: pubmed.ncbi.nlm.nih.gov/34245294/.
Occurrence of de novo cutaneous vasculitis after vaccination against coronavirus disease (COVID-19): pubmed.ncbi.nlm.nih.gov/34599716/.
Asymmetric cutaneous vasculitis after COVID-19 vaccination with unusual preponderance of eosinophils: pubmed.ncbi.nlm.nih.gov/34115904/.
Henoch-Schönlein purpura occurring after vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34247902/.
Henoch-Schönlein purpura following the first dose of COVID-19 viral vector vaccine: case report: pubmed.ncbi.nlm.nih.gov/34696186/.
Granulomatous vasculitis after AstraZeneca anti-SARS-CoV-2 vaccine: pubmed.ncbi.nlm.nih.gov/34237323/.
Acute retinal necrosis due to varicella zoster virus reactivation after vaccination with BNT162b2 COVID-19 mRNA: pubmed.ncbi.nlm.nih.gov/34851795/.
A case of generalized Sweet’s syndrome with vasculitis triggered by recent vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34849386/
Small-vessel vasculitis following Oxford-AstraZeneca vaccination against SARS-CoV-2: pubmed.ncbi.nlm.nih.gov/34310763/
Relapse of microscopic polyangiitis after COVID-19 vaccination: case report: pubmed.ncbi.nlm.nih.gov/34251683/.
Cutaneous vasculitis after severe acute respiratory syndrome coronavirus 2 vaccine: pubmed.ncbi.nlm.nih.gov/34557622/.
Recurrent herpes zoster after COVID-19 vaccination in patients with chronic urticaria on cyclosporine treatment – A report of 3 cases: pubmed.ncbi.nlm.nih.gov/34510694/
Leukocytoclastic vasculitis after coronavirus disease vaccination 2019: pubmed.ncbi.nlm.nih.gov/34713472/803
Outbreaks of mixed cryoglobulinemia vasculitis after vaccination against SARS-CoV-2: pubmed.ncbi.nlm.nih.gov/34819272/
Cutaneous small-vessel vasculitis after vaccination with a single dose of Janssen Ad26.COV2.S: pubmed.ncbi.nlm.nih.gov/34337124/
Case of immunoglobulin A vasculitis after vaccination against coronavirus disease 2019: pubmed.ncbi.nlm.nih.gov/34535924/
Rapid progression of angioimmunoblastic T-cell lymphoma after BNT162b2 mRNA booster vaccination: case report: www.frontiersin.org/articles/10.3389/fmed.2021.798095/
COVID-19 mRNA vaccination-induced lymphadenopathy mimics lymphoma progression on FDG PET / CT: pubmed.ncbi.nlm.nih.gov/33591026/
Lymphadenopathy in COVID-19 vaccine recipients: diagnostic dilemma in oncology patients: pubmed.ncbi.nlm.nih.gov/33625300/
Hypermetabolic lymphadenopathy after administration of BNT162b2 mRNA vaccine Covid-19: incidence assessed by [ 18 F] FDG PET-CT and relevance for study interpretation: pubmed.ncbi.nlm.nih.gov/33774684/
Lymphadenopathy after COVID-19 vaccination: review of imaging findings: pubmed.ncbi.nlm.nih.gov/33985872/
Evolution of bilateral hypermetabolic axillary hypermetabolic lymphadenopathy on FDG PET/CT after 2-dose COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34735411/
Lymphadenopathy associated with COVID-19 vaccination on FDG PET/CT: distinguishing features in adenovirus-vectored vaccine: pubmed.ncbi.nlm.nih.gov/34115709/.
COVID-19 vaccination-induced lymphadenopathy in a specialized breast imaging clinic in Israel: analysis of 163 cases: pubmed.ncbi.nlm.nih.gov/34257025/.
COVID-19 vaccine-related axillary lymphadenopathy in breast cancer patients: case series with literature review: pubmed.ncbi.nlm.nih.gov/34836672/.
Coronavirus disease vaccine 2019 mimics lymph node metastases in patients undergoing skin cancer follow-up: a single-center study: pubmed.ncbi.nlm.nih.gov/34280870/
COVID-19 post-vaccination lymphadenopathy: report of fine-needle aspiration biopsy cytologic findings: pubmed.ncbi.nlm.nih.gov/34432391/
Regional lymphadenopathy after COVID-19 vaccination: review of the literature and considerations for patient management in breast cancer care: pubmed.ncbi.nlm.nih.gov/34731748/
Subclinical axillary lymphadenopathy associated with COVID-19 vaccination on screening mammography: pubmed.ncbi.nlm.nih.gov/34906409/
Adverse events of COVID injection that may occur in children.Acute-onset supraclavicular lymphadenopathy coincident with intramuscular mRNA vaccination against COVID-19 may be related to the injection technique of the vaccine, Spain, January and February 2021: pubmed.ncbi.nlm.nih.gov/33706861/
Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography: pubmed.ncbi.nlm.nih.gov/34116295/
Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F] choline PET / CT, not just an FDG finding: pubmed.ncbi.nlm.nih.gov/33661328/
Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19: pubmed.ncbi.nlm.nih.gov/34050949/
Axillary adenopathy associated with COVID-19 vaccination: imaging findings and follow-up recommendations in 23 women: pubmed.ncbi.nlm.nih.gov/33624520/
A case of cervical lymphadenopathy following COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34141500/
Unique imaging findings of neurologic phantosmia after Pfizer-BioNtech COVID-19 vaccination: a case report: pubmed.ncbi.nlm.nih.gov/34096896/
Thrombotic adverse events reported for Moderna, Pfizer, and Oxford-AstraZeneca COVID-19 vaccines: comparison of occurrence and clinical outcomes in the EudraVigilance database: pubmed.ncbi.nlm.nih.gov/34835256/
Unilateral lymphadenopathy after COVID-19 vaccination: a practical management plan for radiologists of all specialties: pubmed.ncbi.nlm.nih.gov/33713605/
Unilateral axillary adenopathy in the setting of COVID-19 vaccination: follow-up: pubmed.ncbi.nlm.nih.gov/34298342/
A systematic review of cases of CNS demyelination following COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34839149/
Supraclavicular lymphadenopathy after COVID-19 vaccination: an increasing presentation in the two-week wait neck lump clinic: pubmed.ncbi.nlm.nih.gov/33685772/
COVID-19 vaccine-related axillary and cervical lymphadenopathy in patients with current or previous breast cancer and other...
*
Adenopathy after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/33625299/.
Incidence of axillary adenopathy on breast imaging after vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34292295/.
COVID-19 vaccination and lower cervical lymphadenopathy in two-week neck lump clinic: a follow-up audit: pubmed.ncbi.nlm.nih.gov/33947605/.
Cervical lymphadenopathy after coronavirus disease vaccination 2019: clinical features and implications for head and neck cancer services: pubmed.ncbi.nlm.nih.gov/34526175/
Lymphadenopathy associated with the COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/33786231/
Evolution of lymphadenopathy on PET/MRI after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/33625301/.
Autoimmune hepatitis triggered by SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34332438/.
New-onset nephrotic syndrome after Janssen COVID-19 vaccination: case report and literature review: pubmed.ncbi.nlm.nih.gov/34342187/.
Massive cervical lymphadenopathy following vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34601889/
ANCA glomerulonephritis following Modern COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34081948/
Extensive longitudinal transverse myelitis following AstraZeneca COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34507942/.
Systemic capillary extravasation syndrome after vaccination with ChAdOx1 nCOV-19 (Oxford-AstraZeneca): pubmed.ncbi.nlm.nih.gov/34362727/
Unilateral axillary lymphadenopathy related to COVID-19 vaccine: pattern on screening breast MRI allowing benign evaluation: pubmed.ncbi.nlm.nih.gov/34325221/
Axillary lymphadenopathy in patients with recent Covid-19 vaccination: a new diagnostic dilemma: pubmed.ncbi.nlm.nih.gov/34825530/.
Minimal change disease and acute kidney injury after Pfizer-BioNTech COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34000278/
COVID-19 vaccine-induced unilateral axillary adenopathy: follow-up evaluation in the USA: pubmed.ncbi.nlm.nih.gov/34655312/.
Gastroparesis after Pfizer-BioNTech COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34187985/.
Acute-onset supraclavicular lymphadenopathy coincident with intramuscular mRNA vaccination against COVID-19 may be related to the injection technique of the vaccine, Spain, January and February 2021: pubmed.ncbi.nlm.nih.gov/33706861/
Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography: pubmed.ncbi.nlm.nih.gov/34116295/
Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F] choline PET / CT, not just an FDG finding: pubmed.ncbi.nlm.nih.gov/33661328/
Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19: pubmed.ncbi.nlm.nih.gov/34050949/
Axillary adenopathy associated with COVID-19 vaccination: imaging findings and follow-up recommendations in 23 women: pubmed.ncbi.nlm.nih.gov/33624520/
A case of cervical lymphadenopathy following COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34141500/
Unique imaging findings of neurologic phantosmia after Pfizer-BioNtech COVID-19 vaccination: a case report: pubmed.ncbi.nlm.nih.gov/34096896/
Thrombotic adverse events reported for Moderna, Pfizer, and Oxford-AstraZeneca COVID-19 vaccines: comparison of occurrence and clinical outcomes in the EudraVigilance database: pubmed.ncbi.nlm.nih.gov/34835256/
Unilateral lymphadenopathy after COVID-19 vaccination: a practical management plan for radiologists of all specialties: pubmed.ncbi.nlm.nih.gov/33713605/
Unilateral axillary adenopathy in the setting of COVID-19 vaccination: follow-up: pubmed.ncbi.nlm.nih.gov/34298342/
A systematic review of cases of CNS demyelination following COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34839149/
Supraclavicular lymphadenopathy after COVID-19 vaccination: an increasing presentation in the two-week wait neck lump clinic: pubmed.ncbi.nlm.nih.gov/33685772/
COVID-19 vaccine-related axillary and cervical lymphadenopathy in patients with current or previous breast cancer and other malignancies: cross-sectional imaging findings on MRI, CT and PET-CT: pubmed.ncbi.nlm.nih.gov/34719892/
Adenopathy after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/33625299/.
Incidence of axillary adenopathy on breast imaging after vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34292295/.
COVID-19 vaccination and lower cervical lymphadenopathy in two-week neck lump clinic: a follow-up audit: pubmed.ncbi.nlm.nih.gov/33947605/.
Cervical lymphadenopathy after coronavirus disease vaccination 2019: clinical features and implications for head and neck cancer services: pubmed.ncbi.nlm.nih.gov/34526175/
Lymphadenopathy associated with the COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/33786231/
Evolution of lymphadenopathy on PET/MRI after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/33625301/.
Autoimmune hepatitis triggered by SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34332438/.
New-onset nephrotic syndrome after Janssen COVID-19 vaccination: case report and literature review: pubmed.ncbi.nlm.nih.gov/34342187/.
Massive cervical lymphadenopathy following vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34601889/
ANCA glomerulonephritis following Modern COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34081948/
Extensive longitudinal transverse myelitis following AstraZeneca COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34507942/.
Systemic capillary extravasation syndrome after vaccination with ChAdOx1 nCOV-19 (Oxford-AstraZeneca): pubmed.ncbi.nlm.nih.gov/34362727/
Unilateral axillary lymphadenopathy related to COVID-19 vaccine: pattern on screening breast MRI allowing benign evaluation: pubmed.ncbi.nlm.nih.gov/34325221/
Axillary lymphadenopathy in patients with recent Covid-19 vaccination: a new diagnostic dilemma: pubmed.ncbi.nlm.nih.gov/34825530/.
Minimal change disease and acute kidney injury after Pfizer-BioNTech COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34000278/
COVID-19 vaccine-induced unilateral axillary adenopathy: follow-up evaluation in the USA: pubmed.ncbi.nlm.nih.gov/34655312/.
Gastroparesis after Pfizer-BioNTech COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34187985/.
Abbate, A., Gavin, J., Madanchi, N., Kim, C., Shah, P. R., Klein, K., . . . Danielides, S. (2021). Fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 mRNA COVID-19 vaccination in two patients. Int J Cardiol, 340, 119-121. doi:10.1016/j.ijcard.2021.08.018. www.ncbi.nlm.nih.gov/pubmed/34416319
Abu Mouch, S., Roguin, A., Hellou, E., Ishai, A., Shoshan, U., Mahamid, L., . . . Berar Yanay, N. (2021). Myocarditis following COVID-19 mRNA vaccination. Vaccine, 39(29), 3790-3793. doi:10.1016/j.vaccine.2021.05.087. www.ncbi.nlm.nih.gov/pubmed/34092429
Albert, E., Aurigemma, G., Saucedo, J., & Gerson, D. S. (2021). Myocarditis following COVID-19 vaccination. Radiol Case Rep, 16(8), 2142-2145. doi:10.1016/j.radcr.2021.05.033. www.ncbi.nlm.nih.gov/pubmed/34025885
Aye, Y. N., Mai, A. S., Zhang, A., Lim, O. Z. H., Lin, N., Ng, C. H., . . . Chew, N. W. S. (2021). Acute Myocardial Infarction and Myocarditis following COVID-19 Vaccination. QJM. doi:10.1093/qjmed/hcab252. www.ncbi.nlm.nih.gov/pubmed/34586408
Azir, M., Inman, B., Webb, J., & Tannenbaum, L. (2021). STEMI Mimic: Focal Myocarditis in an Adolescent Patient After mRNA COVID-19 Vaccine. J Emerg Med, 61(6), e129-e132. doi:10.1016/j.jemermed.2021.09.017. www.ncbi.nlm.nih.gov/pubmed/34756746
Barda, N., Dagan, N., Ben-Shlomo, Y., Kepten, E., Waxman, J., Ohana, R., . . . Balicer, R. D. (2021). Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med, 385(12), 1078-1090. doi:10.1056/NEJMoa2110475. www.ncbi.nlm.nih.gov/pubmed/34432976
Bhandari, M., Pradhan, A., Vishwakarma, P., & Sethi, R. (2021). Coronavirus and cardiovascular manifestations- getting to the heart of the matter. World J Cardiol, 13(10), 556-565. doi:10.4330/wjc.v13.i10.556. www.ncbi.nlm.nih.gov/pubmed/34754400
Bozkurt, B., Kamat, I., & Hotez, P. J. (2021). Myocarditis With COVID-19 mRNA Vaccines. Circulation, 144(6), 471-484. doi:10.1161/CIRCULATIONAHA.121.056135. www.ncbi.nlm.nih.gov/pubmed/34281357
Buchhorn, R., Meyer, C., Schulze-Forster, K., Junker, J., & Heidecke, H. (2021). Autoantibody Release in Children after Corona Virus mRNA Vaccination: A Risk Factor of Multisystem Inflammatory Syndrome? Vaccines (Basel), 9(11). doi:10.3390/vaccines9111353. www.ncbi.nlm.nih.gov/pubmed/34835284
Calcaterra, G., Bassareo, P. P., Barilla, F., Romeo, F., & Mehta, J. L. (2022). Concerning the unexpected prothrombotic state following some coronavirus disease 2019 vaccines. J Cardiovasc Med (Hagerstown), 23(2), 71-74. doi:10.2459/JCM.0000000000001232. www.ncbi.nlm.nih.gov/pubmed/34366403
Calcaterra, G., Mehta, J. L., de Gregorio, C., Butera, G., Neroni, P., Fanos, V., & Bassareo, P. P. (2021). COVID 19 Vaccine for Adolescents. Concern about Myocarditis and Pericarditis. Pediatr Rep, 13(3), 530-533. doi:10.3390/pediatric13030061. www.ncbi.nlm.nih.gov/pubmed/34564344
Chai, Q., Nygaard, U., Schmidt, R. C., Zaremba, T., Moller, A. M., & Thorvig, C. M. (2022). Multisystem inflammatory syndrome in a male adolescent after his second Pfizer-BioNTech COVID-19 vaccine. Acta Paediatr...
*
Chamling, B., Vehof, V., Drakos, S., Weil, M., Stalling, P., Vahlhaus, C., . . . Yilmaz, A. (2021). Occurrence of acute infarct-like myocarditis following COVID-19 vaccination: just an accidental co-incidence or rather vaccination-associated autoimmune myocarditis? Clin Res Cardiol, 110(11), 1850-1854. doi:10.1007/s00392-021-01916-w. www.ncbi.nlm.nih.gov/pubmed/34333695
Chang, J. C., & Hawley, H. B. (2021). Vaccine-Associated Thrombocytopenia and Thrombosis: Venous Endotheliopathy Leading to Venous Combined Micro-Macrothrombosis. Medicina (Kaunas), 57(11). doi:10.3390/medicina57111163. www.ncbi.nlm.nih.gov/pubmed/34833382
Chelala, L., Jeudy, J., Hossain, R., Rosenthal, G., Pietris, N., & White, C. (2021). Cardiac MRI Findings of Myocarditis After COVID-19 mRNA Vaccination in Adolescents. AJR Am J Roentgenol. doi:10.2214/AJR.21.26853. www.ncbi.nlm.nih.gov/pubmed/34704459
Choi, S., Lee, S., Seo, J. W., Kim, M. J., Jeon, Y. H., Park, J. H., . . . Yeo, N. S. (2021). Myocarditis-induced Sudden Death after BNT162b2 mRNA COVID-19 Vaccination in Korea: Case Report Focusing on Histopathological Findings. J Korean Med Sci, 36(40), e286. doi:10.3346/jkms.2021.36.e286. www.ncbi.nlm.nih.gov/pubmed/34664804
Chouchana, L., Blet, A., Al-Khalaf, M., Kafil, T. S., Nair, G., Robblee, J., . . . Liu, P. P. (2021). Features of Inflammatory Heart Reactions Following mRNA COVID-19 Vaccination at a Global Level. Clin Pharmacol Ther. doi:10.1002/cpt.2499. www.ncbi.nlm.nih.gov/pubmed/34860360
Chua, G. T., Kwan, M. Y. W., Chui, C. S. L., Smith, R. D., Cheung, E. C., Tian, T., . . . Ip, P. (2021). Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination. Clin Infect Dis. doi:10.1093/cid/ciab989. www.ncbi.nlm.nih.gov/pubmed/34849657
Clarke, R., & Ioannou, A. (2021). Should T2 mapping be used in cases of recurrent myocarditis to differentiate between the acute inflammation and chronic scar? J Pediatr. doi:10.1016/j.jpeds.2021.12.026. www.ncbi.nlm.nih.gov/pubmed/34933012
Colaneri, M., De Filippo, M., Licari, A., Marseglia, A., Maiocchi, L., Ricciardi, A., . . . Bruno, R. (2021). COVID vaccination and asthma exacerbation: might there be a link? Int J Infect Dis, 112, 243-246. doi:10.1016/j.ijid.2021.09.026. www.ncbi.nlm.nih.gov/pubmed/34547487
Das, B. B., Kohli, U., Ramachandran, P., Nguyen, H. H., Greil, G., Hussain, T., . . . Khan, D. (2021). Myopericarditis after messenger RNA Coronavirus Disease 2019 Vaccination in Adolescents 12 to 18 Years of Age. J Pediatr, 238, 26-32 e21. doi:10.1016/j.jpeds.2021.07.044. www.ncbi.nlm.nih.gov/pubmed/34339728
Das, B. B., Moskowitz, W. B., Taylor, M. B., & Palmer, A. (2021). Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination: What Do We Know So Far? Children (Basel), 8(7). doi:10.3390/children8070607. www.ncbi.nlm.nih.gov/pubmed/34356586
Deb, A., Abdelmalek, J., Iwuji, K., & Nugent, K. (2021). Acute Myocardial Injury Following COVID-19 Vaccination: A Case Report and Review of Current Evidence from Vaccine Adverse Events Reporting System Database. J Prim Care Community Health, 12, 21501327211029230. doi:10.1177/21501327211029230. www.ncbi.nlm.nih.gov/pubmed/34219532
Dickey, J. B., Albert, E., Badr, M., Laraja, K. M., Sena, L. M., Gerson, D. S., . . . Aurigemma, G. P. (2021). A Series of Patients With Myocarditis Following SARS-CoV-2 Vaccination With mRNA-1279 and BNT162b2. JACC Cardiovasc Imaging, 14(9), 1862-1863. doi:10.1016/j.jcmg.2021.06.003. www.ncbi.nlm.nih.gov/pubmed/34246585
Dimopoulou, D., Spyridis, N., Vartzelis, G., Tsolia, M. N., & Maritsi, D. N. (2021). Safety and tolerability of the COVID-19 mRNA-vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF-inhibitors. Arthritis Rheumatol. doi:10.1002/art.41977. www.ncbi.nlm.nih.gov/pubmed/34492161
Dimopoulou, D., Vartzelis, G., Dasoula, F., Tsolia, M., & Maritsi, D. (2021). Immunogenicity of the COVID-19 mRNA vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF inhibitors. Ann Rheum Dis. doi:10.1136/annrheumdis-2021-221607. www.ncbi.nlm.nih.gov/pubmed/34844930
Ehrlich, P., Klingel, K., Ohlmann-Knafo, S., Huttinger, S., Sood, N., Pickuth, D., & Kindermann, M. (2021). Biopsy-proven lymphocytic myocarditis following first mRNA COVID-19 vaccination in a 40-year-old male: case report. Clin Res Cardiol, 110(11), 1855-1859. doi:10.1007/s00392-021-01936-6. www.ncbi.nlm.nih.gov/pubmed/34487236
El Sahly, H. M., Baden, L. R., Essink, B., Doblecki-Lewis, S., Martin, J. M., Anderson, E. J., . . . Group, C. S. (2021). Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N Engl J Med, 385(19), 1774-1785. doi:10.1056/NEJMoa2113017. www.ncbi.nlm.nih.gov/pubmed/34551225
Facetti, S., Giraldi, M., Vecchi, A. L., Rogiani, S., & Nassiacos, D. (2021). [Acute myocarditis in a young adult two days after Pfizer vaccination]. G Ital Cardiol (Rome), 22(11), 891-893. doi:10.1714/3689.36746. www.ncbi.nlm.nih.gov/pubmed/34709227
Fazlollahi, A., Zahmatyar, M., Noori, M., Nejadghaderi, S. A., Sullman, M. J. M., Shekarriz-Foumani, R., . . . Safiri, S. (2021). Cardiac complications following mRNA COVID-19 vaccines: A systematic review of case reports and case series. Rev Med Virol, e2318. doi:10.1002/rmv.2318. www.ncbi.nlm.nih.gov/pubmed/34921468
Fazolo, T., Lima, K., Fontoura, J. C., de Souza, P. O., Hilario, G., Zorzetto, R., . . . Bonorino, C. (2021). Pediatric COVID-19 patients in South Brazil show abundant viral mRNA and strong specific anti-viral responses. Nat Commun, 12(1), 6844. doi:10.1038/s41467-021-27120-y. www.ncbi.nlm.nih.gov/pubmed/34824230
Fikenzer, S., & Laufs, U. (2021). Correction to: Response to Letter to the editors referring to Fikenzer, S., Uhe, T., Lavall, D., Rudolph, U., Falz, R., Busse, M., Hepp, P., & Laufs, U. (2020). Effects of surgical and FFP2/N95 face masks on cardiopulmonary exercise capacity. Clinical research in cardiology: official journal of the German Cardiac Society, 1-9. Advance online publication. doi.org/10.1007/s00392-020-01704-y. Clin Res Cardiol, 110(8), 1352. doi:10.1007/s00392-021-01896-x. www.ncbi.nlm.nih.gov/pubmed/34170372
Foltran, D., Delmas, C., Flumian, C., De Paoli, P., Salvo, F., Gautier, S., . . . Montastruc, F. (2021). Myocarditis and Pericarditis in Adolescents after First and Second doses of mRNA COVID-19 Vaccines. Eur Heart J Qual Care Clin Outcomes. doi:10.1093/ehjqcco/qcab090. www.ncbi.nlm.nih.gov/pubmed/34849667
Forgacs, D., Jang, H., Abreu, R. B., Hanley, H. B., Gattiker, J. L., Jefferson, A. M., & Ross, T. M. (2021). SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naive and Pre-Immune Humans. Front Immunol, 12, 728021. doi:10.3389/fimmu.2021.728021. www.ncbi.nlm.nih.gov/pubmed/34646267
Furer, V., Eviatar, T., Zisman, D., Peleg, H., Paran, D., Levartovsky, D., . . . Elkayam, O. (2021). Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis, 80(10), 1330-1338. doi:10.1136/annrheumdis-2021-220647. www.ncbi.nlm.nih.gov/pubmed/34127481
Galindo, R., Chow, H., & Rongkavilit, C. (2021). COVID-19 in Children: Clinical Manifestations and Pharmacologic Interventions Including Vaccine Trials. Pediatr Clin North Am, 68(5), 961-976. doi:10.1016/j.pcl.2021.05.004. www.ncbi.nlm.nih.gov/pubmed/34538306
Gargano, J. W., Wallace, M., Hadler, S. C., Langley, G., Su, J. R., Oster, M. E., . . . Oliver, S. E. (2021). Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices – United States, June 2021. MMWR Morb Mortal Wkly Rep, 70(27), 977-982. doi:10.15585/mmwr.mm7027e2. www.ncbi.nlm.nih.gov/pubmed/34237049
Gatti, M., Raschi, E., Moretti, U., Ardizzoni, A., Poluzzi, E., & Diemberger, I. (2021). Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase. Vaccines (Basel), 9(1). doi:10.3390/vaccines9010019. www.ncbi.nlm.nih.gov/pubmed/33406694
Gautam, N., Saluja, P., Fudim, M., Jambhekar, K., Pandey, T., & Al’Aref, S. (2021). A Late Presentation of COVID-19 Vaccine-Induced Myocarditis. Cureus, 13(9), e17890. doi:10.7759/cureus.17890. www.ncbi.nlm.nih.gov/pubmed/34660088
Gellad, W. F. (2021). Myocarditis after vaccination against covid-19. BMJ, 375, n3090. doi:10.1136/bmj.n3090. www.ncbi.nlm.nih.gov/pubmed/34916217
Greenhawt, M., Abrams, E. M., Shaker, M., Chu, D. K., Khan, D., Akin, C., . . . Golden, D. B. K. (2021). The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach. J Allergy Clin Immunol Pract, 9(10), 3546-3567. doi:10.1016/j.jaip.2021.06.006. www.ncbi.nlm.nih.gov/pubmed/34153517
Haaf, P., Kuster, G. M., Mueller, C., Berger, C. T., Monney, P., Burger, P., . . . Tanner, F. C. (2021). The very low risk of myocarditis and pericarditis after mRNA COVID-19 vaccination should not discourage vaccination. Swiss Med Wkly, 151, w30087. doi:10.4414/smw.2021.w30087. www.ncbi.nlm.nih.gov/pubmed/34668687
Hasnie, A. A., Hasnie, U. A., Patel, N., Aziz, M. U., Xie, M., Lloyd, S. G., & Prabhu, S. D. (2021). Perimyocarditis...
*
Hause, A. M., Gee, J., Baggs, J., Abara, W. E., Marquez, P., Thompson, D., . . . Shay, D. K. (2021). COVID-19 Vaccine Safety in Adolescents Aged 12-17 Years – United States, December 14, 2020-July 16, 2021. MMWR Morb Mortal Wkly Rep, 70(31), 1053-1058. doi:10.15585/mmwr.mm7031e1. www.ncbi.nlm.nih.gov/pubmed/34351881
Helms, J. M., Ansteatt, K. T., Roberts, J. C., Kamatam, S., Foong, K. S., Labayog, J. S., & Tarantino, M. D. (2021). Severe, Refractory Immune Thrombocytopenia Occurring After SARS-CoV-2 Vaccine. J Blood Med, 12, 221-224. doi:10.2147/JBM.S307047. www.ncbi.nlm.nih.gov/pubmed/33854395
Hippisley-Cox, J., Patone, M., Mei, X. W., Saatci, D., Dixon, S., Khunti, K., . . . Coupland, C. A. C. (2021). Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. BMJ, 374, n1931. doi:10.1136/bmj.n1931. www.ncbi.nlm.nih.gov/pubmed/34446426
Ho, J. S., Sia, C. H., Ngiam, J. N., Loh, P. H., Chew, N. W., Kong, W. K., & Poh, K. K. (2021). A review of COVID-19 vaccination and the reported cardiac manifestations. Singapore Med J. doi:10.11622/smedj.2021210. www.ncbi.nlm.nih.gov/pubmed/34808708
Iguchi, T., Umeda, H., Kojima, M., Kanno, Y., Tanaka, Y., Kinoshita, N., & Sato, D. (2021). Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report. Drug Saf, 44(11), 1209-1214. doi:10.1007/s40264-021-01104-9. www.ncbi.nlm.nih.gov/pubmed/34347278
In brief: Myocarditis with the Pfizer/BioNTech and Moderna COVID-19 vaccines. (2021). Med Lett Drugs Ther, 63(1629), e9. Retrieved from www.ncbi.nlm.nih.gov/pubmed/34544112https://www.ncbi.nlm.nih.gov/pubme
Ioannou, A. (2021a). Myocarditis should be considered in those with a troponin rise and unobstructed coronary arteries following Pfizer-BioNTech COVID-19 vaccination. QJM. doi:10.1093/qjmed/hcab231. www.ncbi.nlm.nih.gov/pubmed/34463755
Ioannou, A. (2021b). T2 mapping should be utilised in cases of suspected myocarditis to confirm an acute inflammatory process. QJM. doi:10.1093/qjmed/hcab326. www.ncbi.nlm.nih.gov/pubmed/34931681
Isaak, A., Feisst, A., & Luetkens, J. A. (2021). Myocarditis Following COVID-19 Vaccination. Radiology, 301(1), E378-E379. doi:10.1148/radiol.2021211766. www.ncbi.nlm.nih.gov/pubmed/34342500
Istampoulouoglou, I., Dimitriou, G., Spani, S., Christ, A., Zimmermanns, B., Koechlin, S., . . . Leuppi-Taegtmeyer, A. B. (2021). Myocarditis and pericarditis in association with COVID-19 mRNA-vaccination: cases from a regional pharmacovigilance centre. Glob Cardiol Sci Pract, 2021(3), e202118. doi:10.21542/gcsp.2021.18. www.ncbi.nlm.nih.gov/pubmed/34805376
Jaafar, R., Boschi, C., Aherfi, S., Bancod, A., Le Bideau, M., Edouard, S., . . . La Scola, B. (2021). High Individual Heterogeneity of Neutralizing Activities against the Original Strain and Nine Different Variants of SARS-CoV-2. Viruses, 13(11). doi:10.3390/v13112177. www.ncbi.nlm.nih.gov/pubmed/34834983
Jain, S. S., Steele, J. M., Fonseca, B., Huang, S., Shah, S., Maskatia, S. A., . . . Grosse-Wortmann, L. (2021). COVID-19 Vaccination-Associated Myocarditis in Adolescents. Pediatrics, 148(5). doi:10.1542/peds.2021-053427. www.ncbi.nlm.nih.gov/pubmed/34389692
Jhaveri, R., Adler-Shohet, F. C., Blyth, C. C., Chiotos, K., Gerber, J. S., Green, M., . . . Zaoutis, T. (2021). Weighing the Risks of Perimyocarditis With the Benefits of SARS-CoV-2 mRNA Vaccination in Adolescents. J Pediatric Infect Dis Soc, 10(10), 937-939. doi:10.1093/jpids/piab061. www.ncbi.nlm.nih.gov/pubmed/34270752
Kaneta, K., Yokoi, K., Jojima, K., Kotooka, N., & Node, K. (2021). Young Male With Myocarditis Following mRNA-1273 Vaccination Against Coronavirus Disease-2019 (COVID-19). Circ J. doi:10.1253/circj.CJ-21-0818. www.ncbi.nlm.nih.gov/pubmed/34744118
Kaul, R., Sreenivasan, J., Goel, A., Malik, A., Bandyopadhyay, D., Jin, C., . . . Panza, J. A. (2021). Myocarditis following COVID-19 vaccination. Int J Cardiol Heart Vasc, 36, 100872. doi:10.1016/j.ijcha.2021.100872. www.ncbi.nlm.nih.gov/pubmed/34568540
Khogali, F., & Abdelrahman, R. (2021). Unusual Presentation of Acute Perimyocarditis Following SARS-COV-2 mRNA-1237 Moderna Vaccination. Cureus, 13(7), e16590. doi:10.7759/cureus.16590. www.ncbi.nlm.nih.gov/pubmed/34447639
Kim, H. W., Jenista, E. R., Wendell, D. C., Azevedo, C. F., Campbell, M. J., Darty, S. N., . . . Kim, R. J. (2021). Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination. JAMA Cardiol, 6(10), 1196-1201. doi:10.1001/jamacardio.2021.2828. www.ncbi.nlm.nih.gov/pubmed/34185046
Kim, I. C., Kim, H., Lee, H. J., Kim, J. Y., & Kim, J. Y. (2021). Cardiac Imaging of Acute Myocarditis Following COVID-19 mRNA Vaccination. J Korean Med Sci, 36(32), e229. doi:10.3346/jkms.2021.36.e229. www.ncbi.nlm.nih.gov/pubmed/34402228
King, W. W., Petersen, M. R., Matar, R. M., Budweg, J. B., Cuervo Pardo, L., & Petersen, J. W. (2021). Myocarditis following mRNA vaccination against SARS-CoV-2, a case series. Am Heart J Plus, 8, 100042. doi:10.1016/j.ahjo.2021.100042. www.ncbi.nlm.nih.gov/pubmed/34396358
Klein, N. P., Lewis, N., Goddard, K., Fireman, B., Zerbo, O., Hanson, K. E., . . . Weintraub, E. S. (2021). Surveillance for Adverse Events After COVID-19 mRNA Vaccination. JAMA, 326(14), 1390-1399. doi:10.1001/jama.2021.15072. www.ncbi.nlm.nih.gov/pubmed/34477808
Klimek, L., Bergmann, K. C., Brehler, R., Pfutzner, W., Zuberbier, T., Hartmann, K., . . . Worm, M. (2021). Practical handling of allergic reactions to COVID-19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and OGAI. Allergo J Int, 1-17. doi:10.1007/s40629-021-00165-7. www.ncbi.nlm.nih.gov/pubmed/33898162
Klimek, L., Novak, N., Hamelmann, E., Werfel, T., Wagenmann, M., Taube, C., . . . Worm, M. (2021). Severe allergic reactions after COVID-19 vaccination with the Pfizer/BioNTech vaccine in Great Britain and USA: Position statement of the German Allergy Societies: Medical Association of German Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA). Allergo J Int, 30(2), 51-55. doi:10.1007/s40629-020-00160-4. www.ncbi.nlm.nih.gov/pubmed/33643776
Kohli, U., Desai, L., Chowdhury, D., Harahsheh, A. S., Yonts, A. B., Ansong, A., . . . Ang, J. Y. (2021). mRNA Coronavirus-19 Vaccine-Associated Myopericarditis in Adolescents: A Survey Study. J Pediatr. doi:10.1016/j.jpeds.2021.12.025. www.ncbi.nlm.nih.gov/pubmed/34952008
Kostoff, R. N., Calina, D., Kanduc, D., Briggs, M. B., Vlachoyiannopoulos, P., Svistunov, A. A., & Tsatsakis, A. (2021a). Erratum to “Why are we vaccinating children against COVID-19?” [Toxicol. Rep. 8C (2021) 1665-1684 / 1193]. Toxicol Rep, 8, 1981. doi:10.1016/j.toxrep.2021.10.003. www.ncbi.nlm.nih.gov/pubmed/34642628
Kostoff, R. N., Calina, D., Kanduc, D., Briggs, M. B., Vlachoyiannopoulos, P., Svistunov, A. A., & Tsatsakis, A. (2021b). Why are we vaccinating children against COVID-19? Toxicol Rep, 8, 1665-1684. doi:10.1016/j.toxrep.2021.08.010. www.ncbi.nlm.nih.gov/pubmed/34540594
Kremsner, P. G., Mann, P., Kroidl, A., Leroux-Roels, I., Schindler, C., Gabor, J. J., . . . Group, C.-N.-S. (2021). Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : A phase 1 randomized clinical trial. Wien Klin Wochenschr, 133(17-18), 931-941. doi:10.1007/s00508-021-01922-y. www.ncbi.nlm.nih.gov/pubmed/34378087
Kustin, T., Harel, N., Finkel, U., Perchik, S., Harari, S., Tahor, M., . . . Stern, A. (2021). Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. Nat Med, 27(8), 1379-1384. doi:10.1038/s41591-021-01413-7. www.ncbi.nlm.nih.gov/pubmed/34127854
Kwan, M. Y. W., Chua, G. T., Chow, C. B., Tsao, S. S. L., To, K. K. W., Yuen, K. Y., . . . Ip, P. (2021). mRNA COVID vaccine and myocarditis in adolescents. Hong Kong Med J, 27(5), 326-327. doi:10.12809/hkmj215120. www.ncbi.nlm.nih.gov/pubmed/34393110
Lee, E., Chew, N. W. S., Ng, P., & Yeo, T. J. (2021). Reply to “Letter to the editor: Myocarditis should be considered in those with a troponin rise and unobstructed coronary arteries following PfizerBioNTech COVID-19 vaccination”. QJM. doi:10.1093/qjmed/hcab232. www.ncbi.nlm.nih.gov/pubmed/34463770
Lee, E. J., Cines, D. B., Gernsheimer, T., Kessler, C., Michel, M., Tarantino, M. D., . . . Bussel, J. B. (2021). Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. Am J Hematol, 96(5), 534-537. doi:10.1002/ajh.26132. www.ncbi.nlm.nih.gov/pubmed/33606296
Levin, D., Shimon, G., Fadlon-Derai, M., Gershovitz, L., Shovali, A., Sebbag, A., . . . Gordon, B. (2021). Myocarditis following COVID-19 vaccination – A case series. Vaccine, 39(42), 6195-6200. doi:10.1016/j.vaccine.2021.09.004. www.ncbi.nlm.nih.gov/pubmed/34535317
Li, J., Hui, A., Zhang, X., Yang, Y., Tang, R., Ye, H., . . . Zhu, F. (2021). Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study. Nat Med, 27(6), 1062-1070. doi:10.1038/s41591-021-01330-9. www.ncbi.nlm.nih.gov/pubmed/33888900
Li, M., Yuan, J., Lv, G., Brown, J., Jiang, X., & Lu, Z. K. (2021). Myocarditis and Pericarditis following...